Latest price of tazetostat in 2025: Will treatment costs decrease in the future?

Tazemetostat is a targeted drug mainly used to treat relapsed/refractory follicular lymphoma (FL) (non-Hodgkin lymphoma) and epithelioid sarcoma (ES) (soft tissue sarcoma). It has shown good clinical effects, especially for relapsed or refractory patients. This drug prevents the growth and spread of cancer cells by inhibiting EZH2, an epigenetic modification enzyme. It is mainly suitable for the treatment of relapsed or refractory mantle cell lymphoma (FL) and peripheral T-cell lymphoma (PTCL) and other diseases. Through this mechanism, tazerestat can effectively inhibit the proliferation of cancer cells, providing a new treatment option for patients who are ineffective with traditional treatments.

With the launch of tazerestat in China on March 21, 2025, treatment options for many patients have been expanded. However, due to the short time on the market of this drug, the current domestic medical insurance policy has not yet been fully clarified, and many patients still need to purchase this drug through overseas channels. Especially in terms of price, domestic patients have limited purchasing channels, causing a huge financial burden.

At present, the price of foreign original drugs is relatively expensive, especially in the United States and Japan.The price of 200mg 56-pellet drugs is as high as 10,000 to 20,000 yuan. This price prohibits many patients. However, in some countries with low drug production costs, such as Laos, the price of generic drugs is relatively cheap. A 200mg 56-pellet drug is priced at more than 4,000 yuan, which is basically the same composition and effect as the original drug. This provides patients with a less financially burdensome option.

Regarding future treatment costs, with the gradual popularization of tazetostat and the improvement of the domestic market, treatment costs are likely to decrease. As more generic drugs enter the market, price competition will drive overall drug prices down. As the Chinese market further understands the indications of tazetostat and the medical insurance policy gradually covers it, the price of the drug may be gradually reduced under the control of national policies.

Reference materials:https://www.tazverik.com/